Darwish A D, Helal A M, Aly El-Din N H, Solaiman L L, Amin A
Medical Oncology, National Cancer Institute, Cairo University, Cairo, Egypt.
Medical Oncology, National Cancer Institute, Cairo University, Cairo, Egypt.
Breast. 2017 Feb;31:1-8. doi: 10.1016/j.breast.2016.09.018. Epub 2016 Oct 21.
The aim is to identify the epidemiological and clinicopathological features associated with young breast cancer (BC) patients and to discuss factors affecting tumor recurrence and DFS.
PATIENTS & METHODS: A retrospective analysis was conducted based on medical records from young females patients aged ≤35 years with pathologically confirmed primary breast cancer treated during 2008-2010 at NCI. Cases with non invasive cancer and non carcinoma histology are excluded.
Of the 5408 cases diagnosed with breast cancer, 554 were young. Four hundred & fifty eight patients representing 9.2% were within our inclusion criteria. Almost half of the patients (45.9%) presented with stage III. Axillary nodes involvement was in 63.9%, 83.3% were grade 2. More than one quarter of tumors was hormone receptors negative (28.8%) & Her2 was over-expressed in 30%. Mastectomy was offered in 72% while conservative breast surgery in 26%, 69.2% received chemotherapy either adjuvant, neoadjuvant or both, 82.5% received adjuvant radiotherapy, 68.6% received hormonal therapy. Metastatic disease developed in 51.3%, with 31% having more than one site of metastases. After a median follow up period of 66 months, the median DFS of patients was 60 months. The median DFS was significantly shorter among patients with positive lymph nodes (P < 0.0001), ER negative disease (P = 0.045) and stage III disease (P < 0.0001).
Breast cancer in young women is aggressive from the time of diagnosis. Our results provide baseline data of young BC in the Middle East & North Africa region; thus, contributing to future epidemiological and hospital-based researches.
旨在确定与年轻乳腺癌(BC)患者相关的流行病学和临床病理特征,并探讨影响肿瘤复发和无病生存期(DFS)的因素。
基于2008年至2010年期间在国立癌症研究所(NCI)接受治疗的年龄≤35岁、经病理确诊为原发性乳腺癌的年轻女性患者的病历进行回顾性分析。排除非浸润性癌和非癌组织学的病例。
在5408例诊断为乳腺癌的病例中,554例为年轻患者。458例患者(占9.2%)符合纳入标准。几乎一半的患者(45.9%)表现为III期。腋窝淋巴结受累率为63.9%,83.3%为2级。超过四分之一的肿瘤激素受体阴性(28.8%),30%的肿瘤人表皮生长因子受体2(Her2)过度表达。72%的患者接受了乳房切除术,26%接受了保乳手术,69.2%的患者接受了辅助化疗、新辅助化疗或两者皆有,82.5%的患者接受了辅助放疗,68.6%的患者接受了激素治疗。51.3%的患者发生了转移性疾病,31%的患者有一个以上的转移部位。中位随访期为66个月后,患者中位DFS为60个月。淋巴结阳性患者(P < 0.0001)、雌激素受体(ER)阴性疾病患者(P = 0.045)和III期疾病患者(P < 0.0001)的中位DFS明显较短。
年轻女性乳腺癌从诊断时起就具有侵袭性。我们的结果提供了中东和北非地区年轻乳腺癌的基线数据;因此,有助于未来的流行病学和基于医院的研究。